NCT01933763View on ClinicalTrials.gov

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

REGN1193

OTHER

Placebo

Trial Locations (1)

Unknown

Dallas

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01933763 - An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193 | Biotech Hunter | Biotech Hunter